719 related articles for article (PubMed ID: 25995259)
21. Potent
Bardhi A; Wu Y; Chen W; Li W; Zhu Z; Zheng JH; Wong H; Jeng E; Jones J; Ochsenbauer C; Kappes JC; Dimitrov DS; Ying T; Goldstein H
J Virol; 2017 Oct; 91(20):. PubMed ID: 28794022
[TBL] [Abstract][Full Text] [Related]
22. Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent.
Reh L; Magnus C; Schanz M; Weber J; Uhr T; Rusert P; Trkola A
PLoS Pathog; 2015 Jul; 11(7):e1004966. PubMed ID: 26158270
[TBL] [Abstract][Full Text] [Related]
23. Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission.
van Dorsten RT; Reh L; Trkola A; Morris L; Moore PL
J Virol; 2022 Feb; 96(4):e0193421. PubMed ID: 34935437
[TBL] [Abstract][Full Text] [Related]
24. Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization.
Asokan M; Rudicell RS; Louder M; McKee K; O'Dell S; Stewart-Jones G; Wang K; Xu L; Chen X; Choe M; Chuang G; Georgiev IS; Joyce MG; Kirys T; Ko S; Pegu A; Shi W; Todd JP; Yang Z; Bailer RT; Rao S; Kwong PD; Nabel GJ; Mascola JR
J Virol; 2015 Dec; 89(24):12501-12. PubMed ID: 26446600
[TBL] [Abstract][Full Text] [Related]
25. Unique Phenotypic Characteristics of Recently Transmitted HIV-1 Subtype C Envelope Glycoprotein gp120: Use of CXCR6 Coreceptor by Transmitted Founder Viruses.
Ashokkumar M; Aralaguppe SG; Tripathy SP; Hanna LE; Neogi U
J Virol; 2018 May; 92(9):. PubMed ID: 29491151
[TBL] [Abstract][Full Text] [Related]
26. Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6.
Verrier F; Nádas A; Gorny MK; Zolla-Pazner S
J Virol; 2001 Oct; 75(19):9177-86. PubMed ID: 11533181
[TBL] [Abstract][Full Text] [Related]
27. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor.
Pegu A; Yang ZY; Boyington JC; Wu L; Ko SY; Schmidt SD; McKee K; Kong WP; Shi W; Chen X; Todd JP; Letvin NL; Huang J; Nason MC; Hoxie JA; Kwong PD; Connors M; Rao SS; Mascola JR; Nabel GJ
Sci Transl Med; 2014 Jul; 6(243):243ra88. PubMed ID: 24990883
[TBL] [Abstract][Full Text] [Related]
28. What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?
Alexander MR; Ringe R; Sanders RW; Voss JE; Moore JP; Klasse PJ
J Virol; 2015 Jun; 89(11):5981-95. PubMed ID: 25810537
[TBL] [Abstract][Full Text] [Related]
29. HIV-1 Antibody Neutralization Breadth Is Associated with Enhanced HIV-Specific CD4+ T Cell Responses.
Ranasinghe S; Soghoian DZ; Lindqvist M; Ghebremichael M; Donaghey F; Carrington M; Seaman MS; Kaufmann DE; Walker BD; Porichis F
J Virol; 2015 Dec; 90(5):2208-20. PubMed ID: 26656715
[TBL] [Abstract][Full Text] [Related]
30. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
Wieczorek L; Krebs SJ; Kalyanaraman V; Whitney S; Tovanabutra S; Moscoso CG; Sanders-Buell E; Williams C; Slike B; Molnar S; Dussupt V; Alam SM; Chenine AL; Tong T; Hill EL; Liao HX; Hoelscher M; Maboko L; Zolla-Pazner S; Haynes BF; Pensiero M; McCutchan F; Malek-Salehi S; Cheng RH; Robb ML; VanCott T; Michael NL; Marovich MA; Alving CR; Matyas GR; Rao M; Polonis VR
J Virol; 2015 Aug; 89(15):7478-93. PubMed ID: 25972551
[TBL] [Abstract][Full Text] [Related]
31. Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity.
Steinhardt JJ; Guenaga J; Turner HL; McKee K; Louder MK; O'Dell S; Chiang CI; Lei L; Galkin A; Andrianov AK; A Doria-Rose N; Bailer RT; Ward AB; Mascola JR; Li Y
Nat Commun; 2018 Feb; 9(1):877. PubMed ID: 29491415
[TBL] [Abstract][Full Text] [Related]
32. Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells.
Chen Q; Nie J; Huang W; Jiao Y; Li L; Zhang T; Zhao J; Wu H; Wang Y
Hum Vaccin Immunother; 2018 Jan; 14(1):199-208. PubMed ID: 28933644
[TBL] [Abstract][Full Text] [Related]
33. Reactivation of Neutralized HIV-1 by Dendritic Cells Is Dependent on the Epitope Bound by the Antibody.
van Montfort T; Thomas AA; Krawczyk PM; Berkhout B; Sanders RW; Paxton WA
J Immunol; 2015 Oct; 195(8):3759-68. PubMed ID: 26355155
[TBL] [Abstract][Full Text] [Related]
34. Short communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes.
Russell ES; Ojeda S; Fouda GG; Meshnick SR; Montefiori D; Permar SR; Swanstrom R
AIDS Res Hum Retroviruses; 2013 Mar; 29(3):511-5. PubMed ID: 23075434
[TBL] [Abstract][Full Text] [Related]
35. eCD4-Ig Limits HIV-1 Escape More Effectively than CD4-Ig or a Broadly Neutralizing Antibody.
Fellinger CH; Gardner MR; Weber JA; Alfant B; Zhou AS; Farzan M
J Virol; 2019 Jul; 93(14):. PubMed ID: 31068428
[TBL] [Abstract][Full Text] [Related]
36. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
37. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.
Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; Nanlohy NM; van Baarle D; van Nuenen AC; Hessell AJ; Schuitemaker H
J Gen Virol; 2010 May; 91(Pt 5):1354-64. PubMed ID: 20053822
[TBL] [Abstract][Full Text] [Related]
38. Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides.
Hamorsky KT; Grooms-Williams TW; Husk AS; Bennett LJ; Palmer KE; Matoba N
Antimicrob Agents Chemother; 2013 May; 57(5):2076-86. PubMed ID: 23403432
[TBL] [Abstract][Full Text] [Related]
39. Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes.
Su B; Lederle A; Laumond G; Ducloy C; Schmidt S; Decoville T; Moog C
J Virol; 2014 Sep; 88(18):10975-81. PubMed ID: 24965460
[TBL] [Abstract][Full Text] [Related]
40. The Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1.
Liu L; Wang W; Matz J; Ye C; Bracq L; Delon J; Kimata JT; Chen Z; Benichou S; Zhou P
J Virol; 2016 Dec; 90(23):10642-10659. PubMed ID: 27654286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
